Moderna, Inc is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts. It focuses on drug discovery, drug development, and vaccine technologies based on messenger RNA. Moderna's technology platform inserts synthetic nucleoside-modified mRNA into human cells using a coating of lipid nanoparticles. This mRNA then reprograms the cells to prompt immune responses. It is a novel technique, abandoned by other manufacturers due to concerns about the toxicity of lipid nanoparticles at high or frequent doses.
In November 2020, it was announced that the Moderna COVID-19 vaccine candidate, mRNA-1273, had shown preliminary evidence of 94% efficacy in preventing COVID-19 disease in a Phase III trial, with only minor flu-like side effects. This led to its submission for emergency use authorization in Europe, the United States, and Canada. On December 18, 2020, mRNA-1273 was issued an EUA in the United States. On December 23, 2020, it was authorized for use in Canada. On January 6, 2021, it was authorized for use in the European Union. On January 8, 2021, mRNA-1273 was authorized for use in the United Kingdom. On March 15, 2021, mRNA-1283 was started for the phase I clinical trial.
Highest paying job titles at Moderna Therapeutics include Infectious Disease Physician, Clinical Trial Manager, and Director, Regulatory Affairs